Navigation Links
Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting

-- New Subset Analyses To Be Presented --

SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that data from the Company's Phase 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be presented for the first time in the United States at the American Academy of Neurology's 59th Annual Meeting in Boston on Thursday, May 3, at 4:15 p.m. Eastern time. The presentation will include new data from both the mild and moderate subgroups of patients with Alzheimer's disease. Medivation will hold a teleconference on Friday, May 4, at 9:00 a.m. Eastern time with David Hung, M.D., president and chief executive officer of Medivation, Lynn Seely, M.D., chief medical officer, and Rachelle S. Doody, M.D., Ph.D., lead investigator, to discuss the data.

Dr. Doody will present the data (abstract #S51.003), Dimebon Improves Cognition, Function and Behavior in Patients with Mild-Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Study, during the "Aging and Dementia" session of the conference. Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.

In addition, these data have been selected by the American Academy of Neurology for inclusion in the Scientific Topic Highlights session on Thursday, May 3, at 6:00 p.m. Eastern time. During this session, expert moderators will summarize the most interesting and relevant research at the meeting in a particular topic.

Teleconference/Webcast Details

To participate in the live call by telephone, please dial 800-289-0485 from the U.S. or 913-981-5518 internationally. Individuals interested in listening to the live call via webcast may do so by visiting www.medivation.com. A replay of the webcast will be available on the Company's website for 3
'"/>




Page: 1 2 3

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/24/2009)..., MISSISSAUGA,Ontario,Nov.24/PRNewswire-FirstCall/...adeveloperoftechnologyandproductstargetingtheimmun...kChimieS.A.S.("MerckChimie")isprogressingtothenext...arysilvercoatedparamagneticBeads("Beads"). ,, P...rthisyear,CardioGenicssuppliedMerckChimiewithitspr...
(Date:11/24/2009)..., FRANKLIN,Mass.,Nov.24/PRNewswire-FirstCall/--Ech...developingitsneedle-freeSymphony(TM)tCGMSystemasan...onitoring(tCGM)systemanditsPrelude(TM)SkinPrepSyst...rickT.Mooney,M.D.,ChairmanandChiefExecutiveOfficer...maceuticalsConference,sponsoredbytheNewYorkSociety...
(Date:11/24/2009)..., NORTHHOLLYWOOD,Calif.,Nov.24/PRNewswire-FirstCal...leadingnationalhospitalistphysiciangrouppracticeco...IPChospitalist,wasnamedby ACPHospitalist asoneofth...intheNovember2009issueofthemagazine. ,, Dr.Vaid...dcurrentlyservesasdirectorofhospitalmedicineatSt.M...
Breaking Medicine Technology:CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Cell Biosciences Completes Acquisition of Alpha Innotech 5802 1Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 5797 1Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 5797 2Gene Variants Behind Vulnerability to Yeast Infections 60280 1Gene Variants Behind Vulnerability to Yeast Infections 60280 2Gene Variants Behind Vulnerability to Yeast Infections 60280 3
...ng CIMZIA,s long-term benefits and value in,modera... American College,of Gastroenterology (ACG), ORLA...this week by UCB at the American College of Gastro...IMZIA(R) (certolizumab pegol) - the,only PEGylated...ovides,sustained improvement in symptoms with stab...
... 7 , - 125 Patient, Prospective Randomized Placeb...gnificant Improved Overall Survival, Bavarian Nor...m the,therapeutic prostate cancer vaccine candidat...he recently entered partnership with the National,...om the Phase II prospective randomized placebo-con...
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5
(Date:11/24/2009)... The molecular cause of inflammatory bowel d...esented at the upcoming 2009 Advances in Inflammat...s Foundation’s Clinical & Research Confe...y identify a causative mutation for Crohn’s ...Vocus) November 24, 2009 -- The molecular cause of...
(Date:11/24/2009)...s,Nov.24/PRNewswire/--NIP,Inc.todayannouncedtheacq...tion,sleadingexecutivecompensationandbenefitplanpr...ionalofficesinLosAngeles,Milwaukee,Boston,Chicagoa...enownedexpertintheexecutivebenefitsindustry. ,,...readyhassignificantmarketpresence,"statesBillPollo...
(Date:11/24/2009)...NO,Calif.,Nov.24/PRNewswire/--Nextmonth,UnitedHeal...edathelpingHispanic-Americanseniorsunderstandtheba...ragedtotakeafreeZumba®Goldclass,aLatin-infuse...a,cumbia,rumba,andtango. ,, UnitedHealthcarewil...ortableandengagedwhenlearningabouttheirhealthcareo...
(Date:11/24/2009)...Nov.24/PRNewswire/--TheUnionLaborLifeInsuranceComp...dwithVSP(®),()thenation,slargestvisionbenefit...ceproductstounions,uniontrustfunds,unionemployersa...tsofferingservicesincludingcomprehensiveeyeexams,b...howimportantqualityeyecareis,"statedBruceSmith,Nat...
(Date:11/24/2009)...lement may help ward off peripheral artery diseas...(HealthDay News) -- Among people aged 75 and older...vent heart attacks, stroke or death, a new study f... herbal remedy might help prevent the leg-circulat...wever. , Ginkgo contains nutrients called flavo...
Breaking Medicine News(10 mins):Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:NIP Acquires San Diego Executive Benefits Firm 2Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3
...ws Great for Moms and Babies, Bad for Mercury Fear...,seafood consumption guidelines for pregnant women...ers, Healthy Babies Coalition (HMHB), David,Martos...y swung back in the,direction of common sense. For...
...d Center for Geriatric Nursing Excellence in the U...r Hartford centers in the nation, have been funded... nurses have the most recent evidence-based guidel...ic Nursing Collaborative, are in the UI College of...
....J., Oct. 4 Understanding and Treating,Depression...ion produced by,the Multiple Sclerosis Association...ce on depression for both patients and families af...h topics as,the hidden symptoms of depression; war...
...7 National IPF Awareness Week on Capitol Hill Driv...dly Lung Disease, SAN JOSE, Calif., Oct. 4 The C...ced that the success of its fifth,annual National ...fibrosis (IPF), a progressive and ultimately fatal...
...on, wellness, and incentive system meets crucial n...et, FRANKLIN, Tenn., Oct. 4 Fontis Healthcare Se...d incentive support platform for,Group Health Savi...se of HSAs for employers, employees, and insurance...
...., Oct. 4 The following is a,statement regarding ...eople,store their health information online:, It ...le and other IT,leaders plan to develop personal h...Having ready access to your own,health information...
Other Medicine News:Health News:Consumer Group Statement on Seafood and Health: 'We Told You So' 2Health News:Multiple Sclerosis Association of America Publishes Booklet about Depression in Multiple Sclerosis 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Fontis Health Launches Online HSA Support System 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2
...UHTS), Analyst GT delivers unsurpassed multimode a...sfer of assays into screening from assay developme...yst AD and HT, fluorescence intensity, fluorescenc...scence, absorbance, as well as providing seamless ...
...Analyst HT smoothes the transfer of assays into HT...y performance of Analyst AD, fluorescence intensit...cence, luminescence, absorbance. Optimized for se...uding those from Beckman Coulter, Zymark, CRS and ...
...lopment and basic research, including a simple ins...ime required to move assays into HTS. Specifically...ment laboratories, Analyst AD delivers unparallele..., Fluorescence Polarization, Time-Resolved Fluores...
...oplate based multi-detection reader which incorpor...orescence Polarization , Fluorescence Intensity ,...minescence (flash and glow) , Absorbance ,It i...dioactive labeled applications:, , Ca2+ Measuremen...
Medicine Products: